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Abstract: Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular 
diseases such as atherosclerosis. Several pharmacological agents have been developed over 
the past 50 years which target various lipid components such as low density lipoprotein (LDL) 
cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk 
factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be 
complicated and may require combination therapy for effective treatment. This review discusses 
the biochemical mechanisms of action and clinical uses for simvastatin (the most widely avail-
able and commercially prescribed statin) and niacin, and the combination of these agents in the 
management and treatment of dyslipidemia.
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Introduction
‘Multiple dyslipidemia’ is a collective term for the low HDL-cholesterol, elevated 
triglycerides (TG), and small, dense LDL-cholesterol that is often found in insulin-
resistant patients with abdominal obesity, metabolic syndrome, or type 2 diabetes 
(Krauss et al 2004). Current guidelines for the management of cardiovascular risk focus 
ﬁ  rmly on the control of individual cardiovascular risk factors, such as dyslipidemia, 
hypertension, and obesity (NCEP 2002; Grundy et al 2004). For dyslipidemia, these 
guidelines focus ﬁ  rmly on the control of LDL-cholesterol as the primary objective, 
with the control of other lipid components viewed as a secondary objective.
The clinical beneﬁ  ts and safety of statin-based therapy, particularly simvastatin, 
are proven by many well-designed intervention trials (Kastelein et al 2005). Despite 
the impressive beneﬁ  ts with statins, there remains a signiﬁ  cant residual cardiovascular 
risk for events. The National Cholesterol Education Program (NCEP) Adult Treat-
ment Panel (ATP) III guidelines recognize low HDL (1.03 mmol/L or 40 mg/dL) as 
an independent major risk factor for coronary heart disease and as a potential target 
for therapeutic intervention.
The presentation of dyslipidemic phenotypes is heterogeneous, and combination 
therapy with agents (statins) to reduce LDL-cholesterol with agents (eg, niacin and 
ﬁ  brates) that correct low HDL-cholesterol and hypertriglyceridemia provides a rational 
strategy for addressing cardiovascular risk arising from these multiple sources. Niacin 
is an effective pharmacological agent available to increase levels of HDL-cholesterol 
(NCEP 2002), and this compound also induces substantial reductions in TG. Further-
more, niacin therapy shifts the LDL subclass proﬁ  le towards larger, less atherogenic 
particles (McGovern et al 2005). This article will discuss the choice of simvastatin 
and extended release niacin (niacin ER) combination therapy in the management of 
multiple dyslipidemia.Vascular Health and Risk Management 2008:4(5) 1002
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Pharmacology 
and pharmacokinetics 
of niacin ER and simvastatin
Simvastatin
Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-
hexahydro-3-7-dimethyl-8-[2-(tetrahydro-4-hydroxy-
6-oxo-2H-pyran-2-yl)-ethyl]-1naphthalenylester 
[1S[1α,3α,7β,8β(2S*4S*),-8aβ]] (Figure 1). Simvastatin is 
a white to off-white, non-hygroscopic, crystalline powder 
that is practically insoluble in water and freely soluble in 
chloroform, methanol, and ethanol. The empirical formula 
of simvastatin is C25H38O5 and its molecular weight is 418.57 
(Kos Pharma 2008).
Mechanism of action of simvastatin
Simvastatin is a prodrug and is hydrolyzed to its active 
β-hydroxyacid form, simvastatin acid, after administra-
tion. Simvastatin is a speciﬁ  c inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, the 
enzyme that catalyzes the conversion of HMG-CoA to 
mevalonate, an early and rate-limiting step in the biosynthetic 
pathway for cholesterol. In addition, simvastatin reduces 
very low density lipoprotein (VLDL) and TG and increases 
HDL-cholesterol. The pleitropic effects of statins including 
simvastatin have been well studied (Robinson et al 2005).
Niacin
Niacin is nicotinic acid, or 3-pyridinecarboxylic acid. Niacin 
is a white, non-hygroscopic crystalline powder that is soluble 
in water, boiling ethanol, or propylene glycol. It is insoluble in 
ethyl ether. The empirical formula of niacin is C6H5NO2 and its 
molecular weight is 123.11 (Figure 2) (Kos Pharma 2008).
Mechanism of action of niacin
Niacin was found to inhibit lipolysis in adipocytes and reported 
as early as 1960 by Butcher et al (1968), who investigated its 
effect on cyclic AMP. The investigators also found that niacin 
inhibits cyclic AMP production in epinephrine (adrenaline)-
exposed adipocytes. Later work suggested the presence of 
a G-protein-coupled cell surface receptor of the Gig/Go type 
(Aktories et al 1983; Lorenzen et al 2001). In 2003, the 
niacin (nicotinic acid) receptor was identiﬁ  ed as the human 
orphan receptor HM74 or the highly homologous, higher 
afﬁ  nity HM74A, as well as the mouse homolog PUMA-G 
(protein upregulated in macrophages by interferon-[gamma]) 
(Tunaru et al 2003; Wise et al 2003; Soga et al 2003). HM74A 
(GPR109A) and PUMA-G are also identiﬁ  ed as the pharma-
cologically active niacin receptors (Soudijn et al 2007). The 
receptors mediate inhibition of adenyl cyclase in adipocytes 
and thereby block lipolysis, accounting for the marked reduc-
tion of free fatty acids caused by niacin. Furthermore, there 
was an approximately 30% reduction in TG in fat-fed normal 
mice. In receptor-deﬁ  cient mice, no reductions in plasma free 
fatty acid and triglyceride levels were seen (Tunaru et al 2003). 
Substantial mRNA expression of HM74A/PUMA-G was found 
in brown and white adipose tissue, spleen, adrenal, and lung, but 
expression was essentially absent in liver (Wise et al 2003).
Inhibition of lipolysis in adipocytes is a most important 
effect of niacin, but it is not yet proven that antilipolysis 
accounts for all or even most of the effects on plasma lipo-
proteins. Generally, plasma free fatty acid levels appear to 
increase production of VLDL, especially in states of elevated 
free fatty acids and VLDL overproduction (eg, obesity or 
diabetes). After an initial steep fall in plasma free fatty acids 
after ingestion of plain crystalline niacin, however, their 
levels rebound 2 h later, whereas hepatic production of VLDL 
remains suppressed for several additional hours (Wang 
et al 2001). An alternative mechanism, inhibition of hepatic 
diacylglycerol acyltransferase 2 in niacin, has also been 
proposed. In millimolar concentrations, niacin was shown 
to inhibit TG formation in HepG2 cells by diacylglycerol 
acyltransferase 2 inhibition and concomitantly to increase 
apolipoprotein B degradation (Jin et al 1991).
Niacin in millimolar concentrations also inhibited 
the uptake of HDL–apolipoprotein A-I by HepG2 cells 
(a model for liver) without affecting the uptake of cholesteryl 
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Figure 2 Structural formula of niacin.
Figure 1 Structural formula of simvastatin.
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ester from HDL (Jin et al 1997). This is a potential 
mechanism by which niacin raises HDL levels. Moreover, 
niacin is more effective in raising HDL than any other cur-
rently available drug (Guyton et al 2000). The increase in 
HDL–apolipoprotein A-I may augment reverse cholesterol 
transport, allowing removal of greater amounts of choles-
terol from the vascular wall. Recently, niacin (1 mM) was 
shown to activate the peroxisome proliferator-activated 
receptor-[gamma] in a monocytoid cell line, presumably via 
a metabolite of prostaglandin D2. Both cholesterol efﬂ  ux and 
the transcription of efﬂ  ux-related receptors, namely CD36 
and ATP-binding cassette protein A1, were increased by 
niacin. The effect on CD36 was cyclo-oxygenase dependent, 
whereas the effect on ATP-binding cassette protein A1 was 
blocked by an inhibitor of protein kinase A (downstream 
from adenylyl cyclase) (Rubic et al 2004).
Formulations of niacin and its metabolism
Three types of niacin formulations are available: immedi-
ate release, sustained release and extended release. They 
differ in terms of their pharmacokinetic characteristics 
(McKenney et al 2003). Immediate release niacin (niacin IR) 
is absorbed quickly and produces peak serum concentra-
tions within 30–60 min. It is metabolized predominantly 
via conjugation to nicotinuric acid, which is thought to be 
responsible for the ﬂ  ushing associated with niacin therapy. 
Niacin IR is generally given 3 times per day because of its 
rapid pharmacokinetics. Sustained release niacin (niacin 
SR) formulations are absorbed much more slowly, often 
taking 12–24 h (McKenney et al 2003). As a result, this 
preparation is metabolized to a greater extent via oxidation 
to nicotinamide and several pyrimidine breakdown products 
thought to be responsible for the hepatotoxicity associated 
with some SR formulations. Sustained release niacin is gen-
erally taken twice daily, but the absorption characteristics 
vary considerably across products. Extended release niacin 
(niacin ER) has a dissolution rate of 8–12 h and is absorbed 
at a rate intermediate to the other two types of niacin. As a 
result, niacin ER undergoes a more balanced metabolism via 
both pathways, which is believed to contribute to its improved 
safety proﬁ  le. Niacin ER is administered once daily. Niacin 
ER is the only FDA approved form of niacin available within 
the United States for the treatment of dyslipidemia.
Absorption and bioavailability of the 
combination of niacin ER and simvastatin
The relative bioavailability of niacin (nicotinuric acid; Cmax, 
and total urinary excretion as the surrogate), simvastatin, and 
simvastatin acid was evaluated in healthy volunteers (n = 42) 
after administration of two 1000/20 mg niacin/simvastatin 
combination tablets. Niacin exposure (Cmax and AUC) after 
Simcor® (combination pill of simvastatin and niacin ER) was 
similar to that of a niacin ER formulation. However, simv-
astatin and simvastatin acid AUC after Simcor® increased 
by 23% percent and 41%, respectively, compared with those 
of a simvastatin IR. The mean time to Cmax (Tmax) for niacin 
ranged from 4.6 to 4.9 h and simvastatin from 1.9 to 2.0 h. 
Afgter administration of 2 tablets of 1000/20 mg Simcor®, 
the mean Cmax, Tmax, and AUC(0-t) for simvastatin acid, were 
3.29 ng/mL, 6.56 h, and 30.81 ng⋅h/mL respectively (Kos 
Pharma 2008).
Clinical trials on niacin ER 
and simvastatin
Numerous clinical trials have shown the efﬁ  cacy and safety 
of simvastatin in the treatment of hyperlipidemia for sec-
ondary and primary prevention in dyslipidemic patients 
(Scandinavian Simvastatin Survival Study Group 1994). 
The efﬁ  cacy and safety of combination of niacin ER and 
simvastatin have been studied recently (Goldberg et al 2000, 
Taylor et al 2004).
The HATS trial studied the progression of atherosclerosis 
at nine predeﬁ  ned proximal sites in the coronary circulation of 
160 patients with coronary disease and low HDL-cholesterol 
(35 mg/dL in men and 40 mg/dL in women) (Brown 
et al 2001). Three years of treatment with a combination of 
simvastatin and immediate-release nicotinic acid increased 
HDL-cholesterol by 26% and decreased LDL-cholesterol 
by 42%, relative to baseline. These improvements were 
accompanied by regression of atherosclerosis, measured as 
percentage luminal diameter of coronary arteries, compared 
with progression of atherosclerosis on placebo. In compari-
son to placebo, the 3-year primary event rate was reduced 
by 90 percent in patients receiving simvastatin/nicotinic acid 
therapy (p  0.03).
The Arterial Biology for the Investigation of the Treat-
ment Effects of Reducing Cholesterol (ARBITER 2) (Taylor 
et al 2004) study conﬁ  rmed that niacin ER shares these 
anti-atherogenic beneﬁ  ts. ARBITER 2 was a randomized, 
double-blind comparison of niacin ER (1000 mg once 
daily) and placebo when added to existing statin therapy 
in 167 men or women with HDL-cholesterol 45 mg/dL 
and LDL-cholesterol 130 mg/dL. Treatment duration 
was 1 year. The primary endpoint was the change in carotid 
intima-media thickness (cIMT), assessed using ultrasound. 
This endpoint is highly predictive of coronary events, as Vascular Health and Risk Management 2008:4(5) 1004
Pandian et al
shown by a 9-year follow-up of 146 men who underwent 
periodic carotid ultrasound and coronary angiography (Hodis 
et al 1998). The cIMT was signiﬁ  cantly related to the risk 
of coronary events (p  0.02), and an annual increase in 
this parameter of 0.03 mm was associated with a two-fold 
increase in the risk of myocardial infarction or coronary 
heart disease death, and a three-fold increase in the risk of 
any coronary event (p  0.001). The authors concluded that 
measurement of cIMT using ultrasound provided prognostic 
information beyond that available from coronary angiogra-
phy and that cIMT provides a meaningful surrogate marker 
for coronary atherosclerosis.
The ARBITER 2 population was at high risk of coronary 
events. All patients had known coronary heart disease at base-
line as a recruitment criterion, 28 percent had diabetes, 75% 
were hypertensive, and 51% had NCEP/ATPIII metabolic 
syndrome. Mean HDL-cholesterol at baseline was 39 mg/dL 
and mean LDL-cholesterol at baseline was 89 mg/dL. Mean 
HDL-cholesterol did not change in the placebo group but 
was 20% higher after treatment with niacin ER. Niacin ER 
also reduced TG compared with placebo. The lack of effect 
of study treatment on LDL-cholesterol was expected, as 
this parameter was already well controlled by pre-existing 
statin treatment before niacin was administered. Overall, the 
effects on the lipid proﬁ  le of adding niacin to the regimen 
were consistent with the known therapeutic proﬁ  le of this 
agent (Goldberg et al 2000; NCEP 2002).
During treatment with placebo, there was an increase in 
cIMT, whereas no signiﬁ  cant change occurred during treat-
ment with niacin ER, conﬁ  rming the anti-atherogenic proper-
ties of this agent. Indeed, ARBITER 2 was the ﬁ  rst clinical 
trial to demonstrate the superiority of lipid-modifying com-
bination therapy (niacin ER with statin) over monotherapy 
(statin alone) by using cIMT as a clinically validated surrogate 
for coronary atherosclerosis. At the end of the ARBITER 2 
study, 104 patients completed a further 12 months of open-
label treatment with niacin ER. The patients who were on 
placebo were switched to niacin and those on niacin continued 
therapy. The results of this study were termed as ARBITER 3. 
Initial results of ARBITER 3 show that the expected increase 
in HDL-cholesterol occurred in patients switching to niacin 
ER and that atherosclerosis regressed, with a mean reduction 
in cIMT of 0.04 mm from baseline (p = 0.008) after 12–24 
months of treatment with niacin.
The SEACOAST trial (Ballantyne et al 2007) which 
was recently reported is a 24-week double-blind, random-
ized, controlled trial in more than 640 patients with elevated 
non-HDL (type II hyperlipidemia or mixed dyslipidemia) 
compared simvastatin alone to a combination of niacin ER 
and simvastatin. This was a pharmaceutical industry spon-
sored trial. The study was designed to evaluate the safety 
and efﬁ  cacy of Simcor® (combination pill of simvastatin 
and niacin ER) following simvastatin monotherapy. Patients 
enrolled in the trial were assigned to either a low-dose 
(20 mg) or high-dose (40 mg) simvastatin group. Patients in 
the low-dose group were randomized to receive niacin ER 
2000 mg/simvastatin 20 mg, niacin ER 1000 mg/simvastatin 
20 mg, or simvastatin 20 mg. Patients in the high-dose group 
were randomized to receive niacin ER 2000 mg/simvastatin 
40 mg, niacin ER 1000 mg/simvastatin 40 mg or simvastatin 
80 mg. Those in the simvastatin control groups received a 
50 mg dose of niacin IR to maintain blinding.
Patients in the low-dose group receiving combina-
tion treatment achieved 14% (1000 mg/20 mg) and 23% 
(2000 mg/20 mg) reductions in non-HDL compared with 
a 7% reduction with 20 mg simvastatin therapy alone. 
Additionally, combination treatment signiﬁ  cantly improved 
HDL by 18% (1000 mg/20 mg) and 25% (2000 mg/20 mg) 
compared with 7% with 20 mg simvastatin alone. Similarly, 
signiﬁ  cant reductions in TG of 27% (1000 mg/20 mg) and 
38% (2000 mg/20 mg) were seen in those treated with 
combination therapy compared with a 15% reduction with 
simvastatin monotherapy.
In the high-dose group, patients treated with combination 
therapy showed similar (non-inferior) improvements in non-
HDL of 11% (1000 mg/40 mg) and 17% (2000 mg/40 mg) 
compared with a 10% improvement with 80 mg simvastatin 
therapy alone. Additionally, the high-dose combination 
group demonstrated signiﬁ  cant improvements in HDL of 
15% (1000 mg/40 mg) and 22% (2000 mg/40 mg) compared 
with a 1% decrease among those receiving 80 mg simvas-
tatin monotherapy. Triglyceride levels among the high-dose 
combinations groups dropped 23% and 32%, respectively, 
in contrast to a 0.3% increase in those randomized to 80 mg 
simvastatin monotherapy. The study was not designed to 
measure any mortality or outcome data.
Safety and tolerability of niacin ER 
and simvastatin combination
The most common and important side effect of niacin is 
cutaneous ﬂ  ushing, with variable severity among patients. 
Other side effects include hepatic toxicity, hyperglyce-
mia, gout, and rare cases of retinal macular edema. All of 
these effects are dose dependent and fully reversible given 
timely discontinuation. Gastrointestinal side effects, dizzi-
ness, pruritis, headache, and back pain are not uncommon. Vascular Health and Risk Management 2008:4(5) 1005
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Much of the existing perception of niacin adverse effects is 
from studies of the IR and the very-slow release prepara-
tions (Knopp et al 1985). Hepatic toxicity and ﬂ  ushing have 
been favorably affected by recent preparations that attempt 
to strike a beneﬁ  cial balance between the duration and the 
peak levels of plasma drug exposure. The recent publication 
of efﬁ  cacy and safety data for the combination of a statin 
(including simvastatin) and niacin ER in the treatment of 
dyslipidemia (Ballantyne et al 2007; Karas et al 2008; Bays 
2008 ) strongly suggests that the combination therapy would 
be more tolerable than reported in the recent past.
Flushing
Flushing occurs in almost all subjects who take lipid-
modifying doses of niacin IR. It is the major reason for 
discontinuation of the drug, which has been described at 
rates as high as 25%–40% (Knopp et al 1985; Gibbons et al 
1995; McKenney et al 1994). In the Coronary Drug Proj-
ect (CDP Group 1975), the prescribed dose of niacin was 
1000 mg 3 times daily, but mean adherence was only 66%. 
Flushing appears to be decreased and tolerance improved 
with the use of niacin ER, because rates of discontinuation 
of this formulation due to ﬂ  ushing have not exceeded 6% 
in short-term trials (Knopp et al 1998; Goldberg et al 2000; 
Guyton et al 2000).
Flushing is caused by the release of prostaglandin 
D2 and possibly other eicosanoids from cells in the skin 
(Morrow et al 1992). Tachyphylaxis of ﬂ  ushing occurs 
usually with continued use of niacin. Regular, consistent 
dosing over days, weeks, and months reduces frequency 
and severity of ﬂ  ushing, accompanied by lesser increases 
of prostaglandin D2 after niacin ingestion (Stern et al 1991). 
Administering aspirin or other inhibitors of cyclooxygen-
ase 30 min to 1 h before niacin intake can substantially 
reduce ﬂ  ushing (Oberwittler et al 2006). An aspirin dose 
of 325 mg is commonly advised; an 81-mg dose may not 
be enough. Recently, an inhibitor of the prostaglandin D2 
receptor 1 was found to inhibit niacin-induced ﬂ  ushing in 
mice and in early human trials; this compound is under 
clinical development (Cheng et al 2006).
The terms “no-ﬂ  ush niacin” and “ﬂ  ush-free niacin” are 
conventionally used for inositol hexanicotinate. In this com-
pound, 6 molecules of nicotinic acid (niacin) are covalently 
attached to inositol by ester bonds. No published study has 
demonstrated that inositol hexanicotinate releases free niacin, 
demonstrably increases circulating niacin, or alters plasma 
lipid levels. Thus, there is no evidence that niacin in this 
formulation is bioavailable (Meyers et al 2006).
Laropiprant, a prostaglandin D2 receptor-1 antagonist, 
has shown considerable promise in reducing the associated 
ﬂ  ushing with niacin use and shown to improve compliance 
and dosing of niacin ER (Cheng et al 2006; Paolini et al 
2008). This drug in combination with niacin ER is currently 
awaiting FDA approval.
Hyperglycemia
The potential for exacerbation of hyperglycemia in patients 
with diabetes represents another barrier to the successful 
therapeutic use of niacin to correct low HDL-cholesterol. 
Initial studies that suggested the substantial deterioration 
of glycemic control in patients with diabetes occurred in 
patients taking niacin IR. However, these studies used 
niacin doses as high as 4.5 g/day, which are rarely used 
in the statin era to treat hypercholesterolemia (Garg et al 
1990). Clinical studies discussed below, including the 
CDP Study, noted only mild hyperglycemic effects as a 
result of niacin administration (CDP 1975; Canner et al 
1986). Niacin ER at a dose of 2000 mg/day was associated 
with a 5% increase in fasting plasma glucose (Guyton et al 
1998). This hyperglycemia is caused by insulin resistance. 
Only a few studies have quantiﬁ  ed insulin resistance in 
niacin-treated subjects. Some studies have suggested that 
the decrease in insulin sensitivity may average 20%–28% 
after 2 weeks of administration of niacin IR at 1000 mg 
twice daily (Alvarsson et al 1996; Kelly et al 2000; Rasouli 
et al 2005; Chang et al 2006). In subjects aged older than 
60 years, insulin sensitivity decreased by 55%–60% after 
niacin administration. Insulin secretory responsiveness does 
not decrease. In fact, insulin secretion may be increased as 
part of the homeostatic response to the decrease in the effec-
tiveness of insulin action (Kahn et al 1989). The mechanism 
of peripheral insulin resistance may be related to a rebound 
increase in circulating fatty acids but not to increased muscle 
triglyceride content (Poynten et al 2003).
The discussion of niacin-induced insulin resistance is 
important for two clinical reasons. First, hyperglycemia 
itself appears to be associated with worsened cardiovascular 
outcomes (Adler et al 1999). However, it must be recalled 
that the overall impact of niacin is to reduce the residual 
cardiovascular risk associated with statin alone treatment of 
dyslipidemia. The second consequence of insulin resistance 
might be to increase the frequency of new onset of diabetes 
in patients at risk, such as those with the metabolic syndrome. 
Although this is a theoretical possibility, the 5-year CDP did 
not show signiﬁ  cant differences between niacin treated and 
placebo-treated subjects in new prescriptions for insulin, new Vascular Health and Risk Management 2008:4(5) 1006
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prescriptions for oral hypoglycemic drugs, or instances of 
dipstick-positive glycosuria (CDP Research Group 1975).
In the ADMIT study, 64 patients with diabetes and 
peripheral arterial disease, receiving an average niacin dose 
of 2.55 g/day, were compared with 61 similar patients receiv-
ing placebo over 48 weeks. The mean change in hemoglo-
bin A1c (HbA1c) was 0.3% greater in the group receiving 
niacin (p  0.04), and insulin use was 13% more frequent 
in niacin users over the course of the trial, compared with 
4% with placebo (p  0.09) (Elam et al 2000). Likewise, 
HbA1c increased by 0.3% in 52 patients receiving niacin 
ER at 1500 mg/day, compared with no change in 49 patients 
receiving placebo. In this study, niacin-treated patients tended 
to require additional hypoglycemic therapy more often than 
placebo-treated patients (24%–29% of those taking niacin vs 
16% with placebo, p  0.32) (Grundy et al 2002). Thoenes 
et al (2007) reported that in 50 patients with the metabolic 
syndrome treated with niacin ER for 52 weeks, there was a 
signiﬁ  cant improvement in endothelial function and a favor-
able effect on the lipid proﬁ  le. Furthermore, there was no sig-
niﬁ  cant change in glucose intolerance in the study group.
Clinical trials with doses of niacin used clinically today 
appear to result in only minor deterioration of glycemic 
control in most patients with diabetes. The favorable effects 
of niacin on HDL-cholesterol, TG, lipoprotein (a), and 
LDL particle size, along with its lesser effect in lowering 
LDL-cholesterol, probably outweigh the small detriment in 
glycemic control in diabetes.
Hepatotoxicity
McKenney et al (1994) directly compared IR and SR niacin 
in a randomized clinical trial with dosage escalation from 
500 to 3000 mg/day over 30 weeks. None of the 23 patients 
taking niacin IR developed hepatotoxic effects, whereas 12 
of 23 patients (52%) taking niacin SR developed similar 
effects. The increase in liver toxicity with niacin SR mainly 
occurred with doses 1500 mg/day.
Niacin ER and simvastatin can cause abnormal liver tests. 
In a simvastatin-controlled, 24-week study with Simcor® 
in 641 patients, there were no persistent increases (to more 
than 3x the upper limit of normal) in serum transaminases 
(Ballantyne et al 2007). Persistent increases (to more than 
3 times the upper limit of normal) in serum transaminases 
have occurred in approximately 1% of patients who received 
simvastatin in clinical studies (Scandinavian Simvastatin 
Survival Study Group 1994). When drug treatment was 
interrupted or discontinued in these patients, the trans-
aminases levels usually fell slowly to pretreatment levels. 
Liver function tests should be performed on all patients 
during therapy with combination therapy with simvastatin 
and niacin ER. It is recommended that liver function tests be 
performed before treatment begins, every 12 weeks for the 
ﬁ  rst 6 months, and periodically thereafter, at approximately 
6-month intervals (Kos Pharma 2008).
Myopathy and other adverse events
Niacin ER monotherapy has speciﬁ  cally amassed consider-
able clinical trial data that do not support an increased risk 
for muscle adverse experiences with niacin monotherapy. 
Similarly, the safety of niacin ER in combination with statins 
has likewise been assessed, and studies have demonstrated 
no sign of increased muscle toxicity over that of statins alone 
(HATS trial and SEACOAST trial). Many drugs that are 
potent inhibitors of CYP3A4 can increase the risk of myopa-
thy by reducing the elimination of simvastatin. Hence when 
simvastatin is used with a potent inhibitor of CYP3A4, ele-
vated plasma levels of HMGCoA reductase inhibitory activ-
ity can increase the risk of myopathy and rhabdomyolysis, 
particularly with higher doses of simvastatin. In patients with 
renal failure and elderly, caution should be exercised in using 
high doses of statins with niacin ER and may need frequent 
monitoring of muscle and liver enzymes.
Patient perspectives
It is important to counsel patients about the role of niacin in 
improving their lipid proﬁ  le and reducing their cardiovascu-
lar risk. Physicians should review the expected side effects 
with their patients before starting therapy and reinforce the 
importance of staying on therapy. Although most patients can 
expect to experience some ﬂ  ushing even with niacin ER for-
mulations, tolerance to the ﬂ  ushing generally develops with 
continued use. In addition, several measures can reduce the 
frequency and severity of ﬂ  ushing. First, niacin therapy needs 
to be initiated at a low dose and then slowly titrated upward to 
achieve the treatment goal. Second, patients may take aspirin 
325 mg or another non-steroidal anti-inﬂ  ammatory drug 30 
min before the niacin dose to reduce prostaglandin-mediated 
ﬂ  ushing (Oberwittler et al 2006). Third, physicians should 
advise patients to avoid spicy foods, hot beverages, and hot 
showers shortly after taking niacin. Patient should avoid any 
interruptions in niacin therapy to continue any tolerance to 
ﬂ  ushing that has developed. If niacin is interrupted for more 
than 1 week, treatment needs to be restarted at the lowest 
dose and again titrated upward. The niacin ER formulation 
is given at bedtime, which may further reduce the awareness 
of ﬂ  ushing. The simpliﬁ  ed regimen may also improve patient Vascular Health and Risk Management 2008:4(5) 1007
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adherence. Practitioners should discuss these steps with their 
patients and should provide instructions in a written form 
(see Table 1).
Conclusion
The combination of niacin ER with a statin addresses two 
key sources of cardiovascular risk: low HDL-cholesterol 
and elevated LDL-cholesterol. The availability of Niaspan®, 
a prolonged-release formulation of nicotinic acid with 
improved tolerability compared with the immediate-release 
version facilitates the delivery of this therapy. The recently 
published SEACOAST trial (Ballantyne et al 2007) demon-
strated the safety and efﬁ  cacy of combination simvastatin and 
niacin ER in small group of patient population for period of 
6 months. The randomized, double-blind ARBITER 2 study 
(Taylor et al 2004) demonstrated the beneﬁ  ts of Niaspan® 
plus a statin in terms of inhibition of atherosclerosis. 
Although ARBITER 2 was not powered to detect signiﬁ  -
cant differences in event rates, there was a trend towards 
a reduction in cardiovascular events in the Niaspan group, 
compared with placebo.
The Atherothrombosis Intervention in Metabolic Syn-
drome with Low HDL-C/High Triglyceride and Impact on 
Global Health Outcomes (AIM-HIGH) study will explore 
quantitatively the potential of aggressive intervention with 
Niaspan® and a statin to improve cardiovascular event rates. 
This trial, jointly sponsored by the US National Heart, 
Lung, and Blood Institute and Kos Pharmaceuticals Inc (now 
Abbott Pharmaceuticals), is currently recruiting a population 
of 3300 patients with established coronary heart disease, 
atherogenic dyslipidemia (low HDL-cholesterol and high 
TG), and LDL-cholesterol controlled to current US guide-
line goals (NCEP criteria) at 60 sites in the US and Canada. 
Patients will be randomized to receive double-blind treatment 
with Niaspan® plus a statin or to statin monotherapy for 
6 years. The primary outcome measure will be a composite 
of cardiovascular death, non-fatal myocardial infarction, 
non-hemorrhagic stroke, or hospitalization for acute coronary 
syndrome with objective evidence of ischemia. AIM-HIGH 
will deﬁ  ne the potential of aggressive management of both 
low HDL-cholesterol and hyperlipidemia to reduce cardio-
vascular event rates.
The Heart Protection Study 2: Treatment of HDL to 
Reduce the Incidence of Vascular Events (HPS2-THRIVE) is 
an ongoing trial combining simvastatin and extended-release 
niacin plus a D prostanoid 1 receptor antagonist laropiprant, 
to inhibit the prostaglandin D2–mediated ﬂ  ushing side effect 
in comparison with simvastatin monotherapy in 20,000 
patients with coronary heart disease.
In our opinion, the AIM HIGH and HPS2-THRIVE 
studies will give us answers to the question whether the 
combination of simvastatin with niacin ER will reduce 
residual cardiovascular risk in comparison to statin therapy 
alone. At this point of time, the combination of simvastatin 
with niacin ER is an effective treatment of the speciﬁ  c 
components of dyslipidemia, namely improving the pro-
ﬁ  les of elevated TG and LDL-cholesterol and low levels 
of HDL-cholesterol.
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